Beta-CIT-FP

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561193

CAS#: 155797-99-2

Description: Beta-CIT-FP is a cocaine analog. Beta-CIT-FP is a highly potent and selective dopamine uptake inhibitors and a potent DA, 5-HT, and NE uptake inhibitor.


Price and Availability

Size
Price

Size
Price

Size
Price

Beta-CIT-FP is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561193
Name: Beta-CIT-FP
CAS#: 155797-99-2
Chemical Formula: C18H23FINO2
Exact Mass: 431.0758
Molecular Weight: 431.29
Elemental Analysis: C, 50.13; H, 5.38; F, 4.41; I, 29.42; N, 3.25; O, 7.42


Synonym: Beta-CIT-FP; BetaCITFP; Beta CIT FP; FT-beta-CIT; FT beta CIT; FTbetaCIT; FP-Cit; FPCit; FP Cit

IUPAC/Chemical Name: Methyl (1S,3S,4S,5R)-8-(3-fluoropropyl)-3-(4-iodophenyl)-8-azabicyclo[3.2.1]octane-4-carboxylate

InChi Key: HXWLAJVUJSVENX-HZMVEIRTSA-N

InChi Code: InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1

SMILES Code: O=C([C@H]1[C@@H](C2=CC=C(I)C=C2)C[C@]3([H])CC[C@@]1([H])N3CCCF)OC


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Lundkvist C, Halldin C, Ginovart N, Swahn CG, Farde L. [18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol. 1997 Oct;24(7):621-7. PubMed PMID: 9352532.

2: Okada T, Fujita M, Shimada S, Sato K, Schloss P, Watanabe Y, Itoh Y, Tohyama M, Nishimura T. Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines. Nucl Med Biol. 1998 Jan;25(1):53-8. PubMed PMID: 9466362.

3: Günther I, Hall H, Halldin C, Swahn CG, Farde L, Sedvall G. [125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol. 1997 Oct;24(7):629-34. PubMed PMID: 9352533.

4: Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996 Nov;37(11):1760-5. PubMed PMID: 8917170.

5: Lundkvist C, Halldin C, Swahn CG, Hall H, Karlsson P, Nakashima Y, Wang S, Milius RA, Neumeyer JL, Farde L. [O-methyl-11C]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol. 1995 Oct;22(7):905-13. PubMed PMID: 8547888.

6: Rinne JO, Kuikka JT, Bergström KA, Hiltunen J, Kilpelainen H. Striatal Dopamine transporter in Parkinson's disease: A Study With a New Radioligand, [(123)I]B-CIT-FP. Parkinsonism Relat Disord. 1997 Apr;3(2):77-81. PubMed PMID: 18591059.

7: Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Charney DS, Hoffer PB, Neumeyer JL, Innis RB. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996 Jul;37(7):1129-33. PubMed PMID: 8965183.

8: Kuikka JT, Bergström KA, Ahonen A, Hiltunen J, Haukka J, Länsimies E, Wang S, Neumeyer JL. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med. 1995 Apr;22(4):356-60. PubMed PMID: 7607268.

9: Kuikka JT, Akerman K, Bergström KA, Karhu J, Hiltunen J, Haukka J, Heikkinen J, Tiihonen J, Wang S, Neumeyer JL. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain. Eur J Nucl Med. 1995 Jul;22(7):682-6. PubMed PMID: 7498231.

10: Baldwin RM, Zea-Ponce Y, al-Tikriti MS, Zoghbi SS, Seibyl JP, Charney DS, Hoffer PB, Wang S, Milius RA, Neumeyer JL, et al. Regional brain uptake and pharmacokinetics of [123I]N-omega-fluoroalkyl-2 beta-carboxy-3 beta-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol. 1995 Feb;22(2):211-9. PubMed PMID: 7767315.

11: Tissingh G, Bergmans P, Winogrodzka A, Stoof JC, Wolters EC, Booij J, Van Royen EA. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1997 Aug;38(8):1271-2. PubMed PMID: 9255164.

12: Van Laere K, De Ceuninck L, Dom R, Van den Eynden J, Vanbilloen H, Cleynhens J, Dupont P, Bormans G, Verbruggen A, Mortelmans L. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1119-27. Epub 2004 Apr 3. PubMed PMID: 15064872.

13: Ettlinger DE, Häusler D, Wadsak W, Girschele F, Sindelar KM, Mien LK, Ungersböck J, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. Metabolism and autoradiographic evaluation of [(18)F]FE@CIT: a Comparison with [(123)I]beta-CIT and [(123)I]FP-CIT. Nucl Med Biol. 2008 May;35(4):475-9. doi: 10.1016/j.nucmedbio.2008.02.008. PubMed PMID: 18482685.

14: Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, Votaw J, Ely TD, Lambert P, Owens MJ, Camp VM, Malveaux E, Hoffman JM. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol. 2000 Jan;27(1):1-12. PubMed PMID: 10755640.

15: Drewes B, Sihver W, Willbold S, Olsson RA, Coenen HH. New 2alpha-tropane amides as potential PET ligands for the dopamine transporter. Nucl Med Biol. 2007 Jul;34(5):531-9. PubMed PMID: 17591553.

16: Kuikka JT, Yang J, Karhu J, Laitinen T, Tupala E, Hallikainen T, Tiihonen J. Imaging the structure of the striatum: a fractal approach to SPECT image interpretation. Physiol Meas. 1998 Aug;19(3):367-74. PubMed PMID: 9735887.

17: Ogawa O, Umegaki H, Ishiwata K, Asai Y, Ikari H, Oda K, Toyama H, Ingram DK, Roth GS, Iguchi A, Senda M. In vivo imaging of adenovirus-mediated over-expression of dopamine D2 receptors in rat striatum by positron emission tomography. Neuroreport. 2000 Mar 20;11(4):743-8. PubMed PMID: 10757512.

18: Ishiwata K, Kobayashi T, Kawamura K, Matsuno K, Senda M. [11C]Raclopride binding was reduced in vivo by sigma(1) receptor ligand SA4503 in the mouse brain, while [11C]SA4503 binding was not by raclopride. Nucl Med Biol. 2001 Oct;28(7):787-92. PubMed PMID: 11578899.